Lapatinib in patients with metastatic breast cancer following initial treatment with trastuzumab: an economic analysis from the Brazilian public health care perspective
Marcio Machado,1 Thomas R Einarson21GlaxoSmithKline Brasil Ltd, Rio de Janeiro, Brazil; 2Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, CanadaObjective: To evaluate, from the perspective of the Brazilian public health care system, the cost-effectiveness of lapatinib plus capecitabin...
Guardado en:
Autores principales: | Machado M, Einarson TR |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/26edf50c4db44f8d930212a0cd253eea |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Trastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer in Japanese patients
por: Sawaki M
Publicado: (2014) -
Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancer
por: Hurvitz SA, et al.
Publicado: (2012) -
Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer
por: Laura M. Spring, et al.
Publicado: (2021) -
Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models
por: Jamunarani Veeraraghavan, et al.
Publicado: (2021) -
Clinical utility of the combination of lapatinib and letrozole in the management of hormone receptor-positive and HER2-positive advanced breast cancer
por: Merriam PA, et al.
Publicado: (2011)